Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06687564 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Role of ACTG2 Variants in Smooth Muscle Determination and Function in Pediatric Intestinal Pseudo-obstruction.

Study acronym: SMOOTH-PIPO
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Nov 2030 to Feb 3, 2032
    • Start date changed from estimate of Feb 2025 to Feb 4, 2026
    • Site details revised at 3 of 3 sites
    v3
  2. Start date: Nov 2024 to Feb 2025v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objective of this study is to describe the transcriptional impact of R178, R257, R40 or A136 variants of the ACTG2 gene on iPS differentiation mechanisms up to organoids derived from PIPO patient samples versus those derived from control / WT patients (generation of IPS from cultured cell lines), at different stages of their experimental ex vivo development.
Trial Details
NCT Number NCT06687564
Lead Sponsor University Hospital, Grenoble
Conditions
(from sponsor)		 PIPO
Related terms Intestinal Pseudo-Obstruction
Enrollment 4 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov